Stocks to Buy based on the Best Stock Market Research
Very attractive and massive undervalued Biotech Stock with many Major News on the way . Axsome has 4 Phase 3 clinical trials ongoing in various indication targeting very large Markets .This Stock is brutally undervalued with Market cap of $83 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) over 50% of O/S is owned by Insider and Institutions which is a good sign .
This undiscovered goldmine could be the next 10 bagger gem if just oneof their 4 Phase 3 program is successful .GL
Market-Cap: $83 Million
Cash: $50.6 Million
Shares Out: 23 Million
Anticipated Near-Term Clinical Milestones
Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)
Herriott Tabuteau, MD 7 351 729 38,4%
Fidelity Management & Research Co. 2 361 625 12,3%
JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
Mark Coleman, MD 647 998 3,38%
BlackRock Fund Advisors 426 837 2,23%
Stifel Trust Co., NA 415 279 2,17%
The Vanguard Group, Inc. 272 189 1,42%
Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
JPMorgan Investment Management, Inc. 156 625 0,82%
SSgA Funds Management, Inc. 134 688 0,70%
Replies to This Discussion
maybe the cheapest Nasdaq Biotech you can get with 5x Phase 3 in various indications and a laughable Market cap of $85 Million and $50 Million in cash .The fair value should be at $8-10 right now for this unknown Biotech .
Latest stock market analyst ratings:
Brean Capital began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 20 price target on the stock.
Axsome Therapeutics, Inc. had its “” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 27 price target on the stock.
Cantor Fitzgerald began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 13 price target on the stock.
here we go guys we are over $4 ,, this stock is what i call a once in a lifetime opp this stock should be at $20 right now not at laughable $4 .
5 Phase 3 Programs two of them targeting very large Markets with NO approved Drugs .
Marketcap: $90 Million
Cash: $50 Million
AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3 Phase 3 commenced March 2016. Interim analysis due 3Q 2017.
AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) Phase 3 Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.
AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3
AXS-05 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3 Phase 2/3 to be initiated 2Q 2017.
AXS-05 STRIDE-1 Treatment resistant depression Phase 3 Phase 3 initiated March 2016. Top-line data due 1Q 2018.
Need to break the MA(50) at $4.24 then $5+ coming
Fantastic News out today...
Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Alzheimer’s Disease Agitation
Another Guy likes AXSM ...more and more people discover this stock and realize the mega potential here
Nice move today ,, Start Phase 2/3 of Alzheimer agitation trial within days......
Nice price jump looks like its on the way to break the size back the MA(200) at $5.54 .With positive phase 3 results in the coming weeks this low float stock will jump close or even above $10 .
Jumping today, nice stock pick!
2 BIG P3 READOUT THIS MONTH=$$$$$ GET SOME AXSM
AXSM (MC $120 M) (Cash $40 M) Shares Out 25.4 M // 7x Phase 3 programs in various indications targeting billion dollar markets ..2x Phase 3 readout expected within THIS MONTH = Could run to $20+ .Sabby Management just bought 1.4 Million shares a few days ago which is a good sign .GL
Axsome Therapeutics (AXSM)
Market Cap: $120 M
Cash $40 M
Shares Out : 25.4 M ( 16+ Million shares held alone by Management & Institutions)
Presentation from mid November (see slide 36 for upcoming milestones)
Anticipated Near-Term Clinical Milestones
• Clinical Trial Readouts:
Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (late December 2017 to early January 2018)
Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (late December 2017 to early January 2018)
Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1H 2018)
Axsome Therapeutics Inc (AXSM) Stake Owned by Sabby Management, LLC...Dec 4th, 2017
AXSM = Market Cap $70 Million / Cash $41 Million or untill Q4 2019 / Shares Out 25.3 Million / 6x Phase 3 Programs in different indications targeting very large Markets ....Stock is a pure gift at this price